PT3777855T - Métodos de tratamento para doenças fibróticas - Google Patents

Métodos de tratamento para doenças fibróticas

Info

Publication number
PT3777855T
PT3777855T PT201944584T PT20194458T PT3777855T PT 3777855 T PT3777855 T PT 3777855T PT 201944584 T PT201944584 T PT 201944584T PT 20194458 T PT20194458 T PT 20194458T PT 3777855 T PT3777855 T PT 3777855T
Authority
PT
Portugal
Prior art keywords
cholestatic
treatment
methods
fibrotic diseases
fibrotic
Prior art date
Application number
PT201944584T
Other languages
English (en)
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of PT3777855T publication Critical patent/PT3777855T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT201944584T 2016-04-11 2017-03-13 Métodos de tratamento para doenças fibróticas PT3777855T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11

Publications (1)

Publication Number Publication Date
PT3777855T true PT3777855T (pt) 2023-01-10

Family

ID=55755536

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201944584T PT3777855T (pt) 2016-04-11 2017-03-13 Métodos de tratamento para doenças fibróticas
PT177102852T PT3442580T (pt) 2016-04-11 2017-03-13 Métodos de tratamento para doenças colestáticas e fibróticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT177102852T PT3442580T (pt) 2016-04-11 2017-03-13 Métodos de tratamento para doenças colestáticas e fibróticas

Country Status (24)

Country Link
US (7) US20170290812A1 (pt)
EP (3) EP3442580B1 (pt)
JP (1) JP6894923B2 (pt)
KR (1) KR102431257B1 (pt)
CN (1) CN109069648B (pt)
AU (1) AU2017249602B2 (pt)
CA (1) CA3019399A1 (pt)
DK (2) DK3442580T3 (pt)
EA (2) EA202191466A1 (pt)
ES (3) ES2935185T3 (pt)
HR (1) HRP20201954T1 (pt)
HU (2) HUE060671T2 (pt)
IL (1) IL262052B (pt)
LT (1) LT3442580T (pt)
MD (1) MD3442580T2 (pt)
MX (1) MX2018012287A (pt)
MY (1) MY195437A (pt)
PH (1) PH12018502142A1 (pt)
PL (1) PL3442580T3 (pt)
PT (2) PT3777855T (pt)
SG (2) SG10202004425XA (pt)
SI (1) SI3442580T1 (pt)
WO (1) WO2017178172A1 (pt)
ZA (1) ZA201807389B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017249602B2 (en) 2016-04-11 2022-06-16 Genfit Methods of treatment for cholestatic and fibrotic diseases
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
JP7298928B2 (ja) * 2017-03-21 2023-06-27 ノヴァリード ファーマ インク ホスホジエステラーゼの阻害及びその関連障害のための治療剤
EP3709985A1 (en) 2017-11-17 2020-09-23 Köster, Hubert [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
KR20210151854A (ko) * 2019-04-12 2021-12-14 장피트 산화 스트레스와 관련된 질환의 치료에 사용하기 위한 니타족사니드 및 티아졸리드
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
CN114630660A (zh) 2019-10-28 2022-06-14 基恩菲特公司 具有抗氧化特性的联合疗法
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
MX2023005797A (es) * 2020-11-17 2023-05-29 Genfit Metodos de tratamiento de la insuficiencia hepatica.
CN115197164A (zh) * 2021-04-12 2022-10-18 杜心赟 新型噻唑类化合物及其制备方法和用途
CN116077502A (zh) * 2021-11-05 2023-05-09 广州市妇女儿童医疗中心 叶酸在预防、诊断和治疗遗传性、感染性或过敏性疾病中的应用
WO2024074515A1 (en) * 2022-10-04 2024-04-11 Genfit Nitazoxanide for the treatment of hepatic impairment
CN117838690A (zh) * 2023-10-09 2024-04-09 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
EP1983980A4 (en) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
BRPI0815057B8 (pt) 2007-08-03 2021-05-25 Romark Laboratories Lc composto, composição farmacêutica, e, uso de um composto
WO2009023509A2 (en) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9061010B2 (en) 2007-09-18 2015-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
JP2012520884A (ja) * 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
KR20170141830A (ko) 2009-06-26 2017-12-26 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
CA2781054A1 (en) 2009-11-16 2011-05-19 Chung K. Chu 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
KR20200006177A (ko) 2011-03-02 2020-01-17 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
US20120294831A1 (en) 2011-05-16 2012-11-22 Romark Laboratories L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
EP3217795A4 (en) 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
US20170290814A1 (en) 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
AU2017249602B2 (en) 2016-04-11 2022-06-16 Genfit Methods of treatment for cholestatic and fibrotic diseases
AU2017249603B2 (en) 2016-04-11 2022-12-01 Genfit Methods of treatment for cholestatic and fibrotic diseases

Also Published As

Publication number Publication date
US11103484B2 (en) 2021-08-31
PL3442580T3 (pl) 2021-04-06
US10117856B2 (en) 2018-11-06
SG10202004425XA (en) 2020-06-29
US20180092884A1 (en) 2018-04-05
DK3777855T3 (da) 2023-01-09
US20180085354A1 (en) 2018-03-29
US20180092886A1 (en) 2018-04-05
AU2017249602A1 (en) 2018-10-18
ES2928408T3 (es) 2022-11-17
IL262052A (en) 2018-11-29
JP2019513761A (ja) 2019-05-30
US20200316031A1 (en) 2020-10-08
SG11201808402RA (en) 2018-10-30
HUE052886T2 (hu) 2021-05-28
EA201892298A1 (ru) 2019-04-30
US20190000813A1 (en) 2019-01-03
CA3019399A1 (en) 2017-10-19
PH12018502142A1 (en) 2019-07-29
US10117855B2 (en) 2018-11-06
MY195437A (en) 2023-01-20
WO2017178172A1 (en) 2017-10-19
DK3442580T3 (da) 2020-12-21
JP6894923B2 (ja) 2021-06-30
BR112018069684A2 (pt) 2019-01-29
US10130612B2 (en) 2018-11-20
US20170290812A1 (en) 2017-10-12
MX2018012287A (es) 2019-02-07
MD3442580T2 (ro) 2021-04-30
SI3442580T1 (sl) 2021-01-29
LT3442580T (lt) 2020-12-28
CN109069648B (zh) 2022-01-14
EA202191466A1 (ru) 2021-12-31
PT3442580T (pt) 2020-12-23
EP3777854A1 (en) 2021-02-17
EP3777855B1 (en) 2022-10-19
EP3442580B1 (en) 2020-09-23
ES2839453T3 (es) 2021-07-05
ZA201807389B (en) 2020-01-29
IL262052B (en) 2021-12-01
EP3442580A1 (en) 2019-02-20
US20180092885A1 (en) 2018-04-05
HRP20201954T1 (hr) 2021-02-05
EP3777854B1 (en) 2022-07-20
KR20180129934A (ko) 2018-12-05
CN109069648A (zh) 2018-12-21
US10130613B2 (en) 2018-11-20
HUE060671T2 (hu) 2023-04-28
AU2017249602B2 (en) 2022-06-16
KR102431257B1 (ko) 2022-08-10
EP3777855A1 (en) 2021-02-17
ES2935185T3 (es) 2023-03-02

Similar Documents

Publication Publication Date Title
ZA201807389B (en) Methods of treatment for cholestatic and fibrotic diseases
ZA201807084B (en) Methods of treatment of cholestatic diseases
ZA202006746B (en) Methods of treatment
HK1246179A1 (zh) 治療視網膜疾病的方法
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
HRP20181914T1 (hr) Liječenje intrahepatičnih kolestatskih bolesti
ZA201807390B (en) Methods of treatment for cholestatic and fibrotic diseases
IL274541A (en) A method for treating diseases of the digestive tract using Tradifitant
HK1258994A1 (zh) 用於疾病治療的方法
ZA201808360B (en) Treatment of intrahepatic cholestatic diseases
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
HK1255691A1 (zh) 對疾病進行組織學診斷和治療的方法
HK1245671A1 (zh) 使用白細胞介素-10治療疾病和病症的方法
HK1243937A1 (zh) 治療疾病的方法
EP3151824A4 (en) Methods of treating neurodevelopmental diseases and disorders
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201500555D0 (en) Method and device for the treatment of diseases
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201414023D0 (en) Treatment of autoimmune diseases
AU2014902173A0 (en) Methods of treating neurodevelopmental diseases and disorders